Final Analysis of Post‐Marketing Surveillance for Avelumab + Axitinib in Patients With Renal Cell Carcinoma in Japan
ABSTRACT Introduction Avelumab, an anti‐programmed death ligand 1 antibody, was approved in combination with axitinib for curatively unresectable or metastatic renal cell carcinoma (RCC) in Japan in December 2019. Because the pivotal JAVELIN Renal 101 study included a limited number of Japanese pati...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.70275 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|